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Abbreviation Meaning 
 
PRP 
PPP 
ECM 
PDGF 
FGF 
EGF 
TGF-α / TGF-β 
KGF 
HGF 
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IGF 
PDAF 
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Ca2+ 
PT 
PTT 
aPTT 
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Platelet Derivated Growth Factor 
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Transforming Growth Factor α / β 
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Vacular Endothelial Growth Factor 
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Platelet-derived Angiogenesis Factor 
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Partial thromboplastin time 
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Von Willebrand Disease 
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Abstract 
Introduction: The process of tissue healing in the oral cavity involves a series of as 
well orchestrated cell-cell interactions. For the healing to occur properly it is 
necessary that immediately after the injury, and with the disruption of the vasculature, 
be established the formation of the clot with fibrin formation, platelet aggregation and 
release of many growth factors into the tissue. Based on this concept, comes the 
platelet rich plasma (PRP), a supplement that is rich in growth factors and which 
allows their liberation in order to assist and improve the tissue healing. Patients with 
hemostatic impairment, undergoing oral surgery, are at risk of further complications 
such as excessive bleeding and difficulties in healing and are therefore adequate 
candidates to the use of PRP. 
Objectives: Understand the clinical applications and therapeutic relevance of the use 
of PRP in the processes of tissue healing in patients with bleeding disorders and know 
the clinical protocol of PRP for this type of patients. 
Materials and Methods: A literature search was performed in the database 
"Pubmedl®" and “Google Scholar”, through scientific articles. 
Discussion: PRP is used in the functional recovery of tissues, which play an important 
role in accelerating the mechanisms of repair and tissue regeneration. This is obtained 
by low speed centrifugation of a blood sample, preferentially removed from the own 
patient, and four types of formulations can be obtained. The PRP has multiple 
applications in dentistry and is mainly used in bone grafts, alveolar surgical repair 
after tooth extraction, treatment of intrabony periodontal defects and implant 
placement. This is now also been applied, successfully, in patients with bleeding 
disorders for improving post-operative healing conditions and faster recovery and 
regeneration of oral tissues and control bleeding immediately after surgery. 
Conclusions: Despite the evidence that PRP helps in healing, hemorrhage control and 
repair of oral tissues process, there are few studies that demonstrate its effectiveness 
in patients with bleeding disorders. 
 
 
Key words: platelet-rich plasma, PRP applications, bleeding disorders, prevention of 
bleeding, coagulation problems, oral surgery, dental medicine. 
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Resumo 
Introdução: O processo de cicatrização tecidular na cavidade oral envolve uma série 
de interações célula-célula bem orquestradas. Para que a cicatrização ocorra de forma 
adequada é necessário que logo após a lesão, e com a interrupção da vasculatura, se 
verifique a formação do coágulo com formação de fibrina, agregação de plaquetas e 
libertação de vários fatores de crescimento para os tecidos. Tendo por base este 
conceito, surge o plasma rico em plaquetas (PRP), um complemento rico em factores 
de crescimento e que permite a sua libertação de forma a facilitar o processo de 
reparação tecidular. Pacientes com comprometimento hemostático, que se submetam 
a cirurgias orais, correm o risco de complicações adicionais como sangramento 
excessivo e dificuldades na cicatrização, sendo por isso considerada a utilização do 
PRP. 
Objetivos: Compreender as aplicações clínicas e relevância terapêutica da utilização 
do PRP nos processos de cicatrização de tecidos, em pacientes com coagulopatias e 
saber o protocolo clínico de formulação do PRP para este tipo de pacientes. 
Material e Métodos: A pesquisa bibliográfica foi realizada na base de dados 
"Pubmedl®" e "Google Scholar", através de artigos científicos. 
Desenvolvimento: O PRP é usado na recuperação funcional dos tecidos, 
desempenhando um papel importante na aceleração dos mecanismos de reparação e 
regeneração tecidular. Este é obtido pela centrifugação a baixa velocidade de uma 
amostra de sangue, preferencialmente retirada do próprio paciente, podendo ser 
obtidos 4 tipos de formulações. O PRP tem múltiplas aplicações e na Medicina Dentária 
é usado principalmente em enxertos ósseos, reparo cirúrgico alveolar após extração 
dentária, tratamento de defeitos periodontais infra-ósseos e na colocação de 
implantes. O PRP está agora a ser também aplicado, e com sucesso, em pacientes com 
coagulopatias para melhorar as condições pós-operatórias de cicatrização e de forma a 
acelerar a recuperação e regeneração dos tecidos orais e controlar a hemorragia 
imediatamente após a cirurgia. 
Conclusões: Apesar de estar provado que o PRP ajuda na cicatrização, controlo de 
hemorragia e processo de reparação dos tecidos orais, ainda há poucos estudos que 
evidenciam essa eficácia nos pacientes com distúrbios hemorrágicos. 
 
Palavras-chave: Plasma rico em plaquetas, aplicações do PRP, coagulopatias, 
prevenção do sangramento, problemas de coagulação, cirurgia oral, medicina dentária. 
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Introduction 
 Wound healing in general can be defined as the physiology by which the 
body replaces and restores function to damaged tissues; a process to a state of 
soundness any injury 1.  
Within the oral cavity, the gingiva is lined by stratified squamous epithelium 
that is a boundary between the external environment and underlying connective 
tissue. Gingival wounds or surgical procedures, such as tooth extractions, 
periodontal or implant surgery or bone grafts, involve disruption of this barrier 
function 2.  
The process of tissue healing in the oral cavity consists of a seamless and 
coordinated chain of cellular and molecular events that interact in order to assure 
the restructuring and constitution of the tissues. This event is a dynamic process 
that implicates a series of well-orchestrated cell-cell interactions between 
epithelial cells, gingival fibroblasts, osteoblasts and periodontal ligament 
fibroblasts 3, 4, 5. For healing to occur properly and in order to guarantee the 
restoration of tissue, it is necessary that immediately after the injury, and 
disruption of the vasculature, there is clot formation with fibrin formation, platelet 
aggregation and release of some growth factors into the tissue 3, 4, 5. 
The wound healing process (Figure 1) is classically demarcated by series of 
continuous, sometimes overlapping, events and can be divided into three major 
phases: inflammation, proliferation and remodeling. The first occurs immediatly 
after injury and may continue for up to 6 days and is characterized by hemostasis, 
constriction of the blood supply, release of growth factors, platelet aggregation and 
degranulation, clot formation resulting in fibrin and migration of phagocytic 
leukocytes that secretes chemicals which kills and removes foreign substances and 
microorganisms of the wound. The second (5 days to 3 weeks) is characterized by 
the formation of the extracellular matrix (ECM) and mainly involves the migration 
and proliferation of three cell classes: fibroblasts, endothelial cells and 
keratinocytes. These cells proliferate in response to growth factors and cytokines 
(released from macrophages, platelets, and mesenchymal cells, or that were stored 
in the fibrin clot). In addition to chemotactically drawing fibroblasts into the 
wound, there are many growth factors that induce cellular activation and 
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proliferation (Table 1). Then, proliferating cells respond by releasing collagen and 
glycosaminoglycans (mainly hyaluronic acid, chondroitin-4-sulphate, dermatan 
sulphate, and heparin sulphate). The combination of the secreted products forms 
the new ECM, which is determinant for the organization of granulation tissue that 
eventually fills the wound. The formation of new blood vessels (angiogenesis) 
accompanies fibroblast proliferation and allows nutrients and healing factors to 
enter the wound space. In the third and final phase (from 3 weeks to 2 years) 
change occurs in the pattern of collagen organization and its main type, occurring 
replacement of collagen type III by collagen type I, increasing the tensile strength 
of the scar tissue because of the amplification of cross-links between monomers of 
this substance 6, 7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Main phases and factors of the wound healing process (adapted from Larjava H. 2012) 8 
 
 
 
 
Epithelial proliferation 
Monocyte chemotaxis 
EGF, TGF-α, KGF, HGF 
PDGF, FGF, TGF-β 
Fibroblast migration PDGF, FGF, TGF-β 
Fibroblast proliferation PDGF, EGF, FGF, TNF 
Angiogenesis VEGF, Angiopoietin, FGF 
Collagen synthesis TGF-β, PDGF 
Collagenase secretion PDGF, FGF, EGF, TNF; TGF-β inhibits 
 
Table I: Growth Factors and Cytokines Affecting Various Steps in Wound Healing (adapted from Kumar V. 2007) 9 
Hemostasis 
Inflammation 
Proliferation 
Remodelling 
Scar tissue 
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A valuable complement which is now occasionally used in functional 
recovery of tissues and that plays an important role in the acceleration of the 
mechanisms of tissue regeneration and repair is the Platelet-rich plasma (PRP) 3, 4, 
10. PRP is applied in many surgical fields, such as, orthopaedics, ophthalmology, 
head and neck surgery, otolaryngology, cardiovascular surgery, maxillofacial 
surgery and healing therapies of bone, muscle, tendon and cartilage injuries10, 11, 12. 
PRP is a rich source of growth factors, used in many techniques in dental 
and oral surgery to stimulate the healing process 3, 10, 13. It is defined as a high 
concentration of autologous platelets in a small volume of plasma, that mimics the 
natural ways of wound healing 4, 10, 14. Platelets contribute to hemostasis by 
preventing blood loss at sites of vascular injury, and they contain a large number of 
growth factors and cytokines that have a key role in bone regeneration and soft-
tissue maturation 15.  
Drago L. et al (2013) investigated the antimicrobial properties of pure PRP 
and its effects on surgeries in the oral cavity, and he concluded that PRP is very 
useful in the reduction of postoperative infections, because it inhibits the growth of 
Enterococcus faecalis, Candida albicans, Streptococcus agalactiae and Streptococcus 
oralis 16. 
Wound healing may be changed by a variety of influences, frequently 
reducing the quality or adequacy of the reparative process. This is the case of 
patients with bleeding disorders 9. Patients with compromised hemostasis, after 
oral surgery procedures have risks of additional complications, such as 
uncontrolled and excessive bleeding and difficulty in healing and is therefore 
considered the use of PRP 17, 18. 
Thus, it becomes essential understand how the use of platelet-rich plasma 
can influence and help in the healing process of these patients in order to ensure a 
better and faster recovery and greater treatment success. 
Accordingly, this paper aims to understand the clinical applications and 
therapeutic relevance of the use of platelet rich plasma in the processes of tissue 
healing in patients with coagulopathies and know the clinical protocol of PRP for 
this type of patients, particularly the question of the use of autologous blood or 
blood from other patients with blood compatibility. 
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Material and Methods 
For this paper, a review of scientific literature was conducted about the 
concept of platelet-rich plasma and the results of its application in patients with 
bleeding disorders. As a result, a literature search was performed in the database 
"Pubmed ®" and “Google Scholar”, through scientific articles and specialty papers. 
The following keywords were used: “platelet-rich plasma”, “PRP 
applications”, “bleeding disorders”, “prevention of bleeding”, “coagulation problems”, 
“and oral surgery”, “dental medicine”. 
In the survey no restriction was used due to the difficulty in fully access to 
all articles and the insufficiency of content, however, after a first analysis, the 
articles selection was limited to english and portuguese language and to the last 10 
years. 
After reading the abstracts and a brief analysis of the full article, the articles 
that presented studies in animals and articles that reference studies in 
anticoagulated patients, were excluded. 
Thus, 46 articles were included in this work, relating to reliable and 
scientific clinical studies and were also used 3 books. 
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Discussion 
PRP Generalities and Overview 
Platelet-rich plasma is a volume of autologous plasma that has a high 
concentration of platelets, above baseline, and it has provided an advance in the 
acceleration and stimulation of bone and soft tissue healing, because it is a rich 
source of growth factors 3, 4, 10. PRP is a platelet concentration with at least 
1.000.000/1rL in a 5 mL volume of plasma, when normal human platelet counts in 
the blood range from 150.000/1 L to 350.000/1 L 10. 
 Platelets participate actively in the healing process of wounds. They are the 
first component that is present at the site of trauma and exhibit anti-inflammatory 
and regenerative properties. Once activated, platelets release growth factors 
present in alpha granules, which have an important role in the healing process. 
These growth factors are a group of polypeptides, which have a significant action 
at various stages of tissue repair, acting as regulators and stimulators of cellular 
processes of mitogenesis, chemotaxis, differentiation and metabolism. These 
factors include a number of proteins, commonly known as platelet derived growth 
factors 13. These growth factors present in PRP include PDGF (PDGF-αα, PDGF-ββ e 
PDGF-αβ), TGF-β (TGF- β1 e TGF-β2), IGF (IGF-1 e IGF-2), Vascular endothelial 
growth factor (A and C), FGF-2, PDEGF, HGF, PDAF, PF-4, as depicted in Table II 3, 4, 
10, 11, 13, 19, 20.    
Growth 
factor 
Source cells Target Biological functions 
PDGF 
Platelets, 
macrophages, 
monocytes, 
endothelial cells, 
smooth muscle cells 
Fibroblasts, smooth 
muscle cells, glial cells, 
macrophages/neutrophils 
Stimulates chemotaxis/mitogenesis in 
fibroblast/glial/smooth muscle cells; 
regulates collagenase secretion/ collagen 
synthesis; stimulates 
macrophage/neutrophil chemotaxis 
TGF-β 
Platelets, T-
lymphocytes, 
macrophages/mono
cytes, neutrophils 
Fibroblasts, marrow stem 
cells, endothelial cells, 
epithelial cells, 
preosteoblasts 
Stimulates/inhibits endothelial, fibroblastic, 
and osteoblastic mitogenesis; regulates 
collagen synthesis/collagenase secretion; 
regulates mitogenic effects of other growth 
factors; stimulates endothelial chemotaxis 
and angiogenesis 
PDEGF 
Platelets, 
macrophages, 
monocytes 
Fibroblasts, endothelial 
cells, epithelial cells 
Stimulates endothelial 
chemotaxis/angiogenesis; regulates 
collagenase secretion; stimulates 
epithelial/mesenchymal mitogenesis 
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PDAF 
Platelets, endothelial 
cells 
Endothelial cells Increases angiogenesis and vessel 
permeability; stimulates mitogenesis for 
endothelial cells by direct or indirect 
actions; several cytokines and growth 
factors up-regulate PDAF, including IGF-1, 
TGF alpha and beta, PDGF, bFGF, PDEGF, 
and IL-1 beta 
IGF-1 
Osteoblasts, 
macrophages, 
monocytes, 
chondrocytes 
Fibroblasts, osteoblasts, 
chondrocytes 
Stimulates cartilage growth, bone matrix 
formation, and replication of preosteoblasts 
and osteoblasts; acts as an autocrine and 
paracrine factor; in combination with PDGF 
can enhance the rate and quality of wound 
healing 
PF-4 
Platelets Fibroblasts, neutrophils Chemoattractant for neutrophils and 
fibroblasts; potent antiheparin agent 
 
 
 
Table II: Summary of Growth Factors Released from Platelets. (Adapted from Sánchez A. 2003) 19 
  
Because of its individualities, PRP is used in many procedures in dental and 
oral surgery such as ablative surgical procedures, bone grafts, mandibular 
reconstruction and repair of the alveolar cleft, treatment of periodontal plastic 
surgery and infrabony periodontal defects, even as procedures related to the 
placement of osseointegrated implants 10, 13. 
 The advantages of these clinical uses of PRP are the contribution to 
accelerate postoperative wound healing and tissue repair and rapid 
revascularization and re-epihelialization. Because it is autologous, it eliminates 
concerns about immunogenic reactions and infectious diseases transmition 3, 10, 13, 
15, 19. 
 The single disadvantage of PRP is their preparation, the cost versus 
outcome benefit. The cost of the PRP-processing system for the clinician, and the 
disposable kits, compared to the uncertain success, may not justify their purchase. 
The cost for the patient to pay for this treatment is also high and the fact to be 
subjected to a venipuncture and blood drawing procedure is also a limitation 10. 
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PRP Preparation and formulation  
Firstly, blood collection from patient is performed in tubes containing 
sodium citrate as anticoagulant, because this element does not modify the platelet 
membrane receptors and consequently preserves the platelets’ integrity. 
Successively, centrifugation is achieved in a specifically designed centrifuge that 
has parameters to maximize the production of platelets and keep the plasma 
leucocyte free 4, 13. 
The device must use a double centrifugation method (Figure 3). The first 
centrifugation step (termed the hard spin) separates the red blood cells from the 
plasma. This plasma contains the white blood cells, the platelets, and the clotting 
factors. The second step (named soft spin) separates the white blood cells and the 
platelets together with a few red blood cells from the plasma. This last spin 
separates PRP from the PPP, free from the obstruction provided by a large number 
of red blood cells and produces the factual PRP 13, 19, 21.  
To attempt the production of PRP with a single spin would not produce a 
true PRP. A single spin in the production of PRP would not produce a true PRP, but 
instead, a mixture of PRP and PPP, which have low platelet counts. Regardless of 
the rate of centrifugation or the time of centrifugation, only one spin cannot 
adequately obtain a concentrate of platelets, because the red blood cells will 
interfere with the fine separation of the platelets 20. 
After centrifugation 3 typical layers can be 
obtained: an upper yellowish layer (plasma), which 
contains a gradient of platelets, a thin intermediate 
white layer containing leucocytes (buffy coat), and a 
lower dense layer containing the red cells (like is 
demonstrated in Figure 2) 4, 12.  
 
Figure 2: Blood physiology after centrifugation.  
 
 
 
 
Figure 3: Centrifugations 
carried out in the PRP 
preparation  
(Sánchez A. 2003) 19.  
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Some available systems and PRP preparation methods use bovine thrombin 
as anticoagulant to activate the clotting mechanism and to induce platelet 
activation, however, some studies have associated the use of bovine thrombin with 
development of antibodies to human clotting factors V, XI, and thrombin, resulting 
in a risk of potentially life-threatening coagulopathies 19, 21, 22. 
From the patient’s blood, four different formulations with therapeutic 
potential can be obtained: a 3-dimensional scaffold, the liquid formulation, the 
supernatant and the elastic and dense autologous fibrin membrane (Figure 4) 4. 
Accordingly, PRP may be mixed into a bone graft, sprayed on a soft tissue surface, 
layered in as the graft is placed, or used as a biological membrane 4, 15. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Different types of PRP presentations and formulations. Adapted from Anitua E, et al. 2012 (Without 
author permission) 4 
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Figure 5: Overview of hemostasis 
and tissue repair. 
Normal Hemostasis 
Under normal conditions, hemostasis (or the arrest of bleeding) occurs 
through 2 independent, but linked processes: the coagulation cascade and the 
platelet activation pathway 23. 
The first step in hemostasis process is the immediate constriction of 
damaged vessels, which temporarily reduces the flow and pressure within the 
vessel, aiding in the formation of a platelet plug. Then, there is a mechanical 
blockage of the orifice by the platelet plug. The platelets bind to exposed collagen 
and become activated by releasing cytokines in the area around the lesion. Other 
platelet factors reinforce local vasoconstriction and further activate platelets, 
which are grouped with each other. Subsequently, the exposed collagen and the 
factors present in tissues, initiate a series of reactions known as the coagulation 
cascade (Figure 5) 23. 
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Figure 6: Coagulation cascade: the intrinsic, extrinsic and common pathways (Kumar V. 2007) 9 
 
The coagulation cascade (Figure 6) is a sequential series of enzymatic 
reactions that ends with the formation of a network of elastic fibers which 
stabilizes and strengthens the platelet plug and turns it into hemostatic plug; it is 
the conversion of a soluble plasma protein (fibrinogen) into an insoluble polymer 
(fibrin). Some chemical factors involved also contribute to adhesion and 
aggregation of platelets in the damaged region. Coagulation is divided into two 
pathways: the intrinsic pathway (dependent on contact activation by a negatively-
charged surface, and involving coagulation factors XII, XI, IX, VIII and V), and the 
extrinsic pathway (dependent on tissue-factor being exposed to the circulation, 
and involving tissue factor and factor VII), that converge on a common pathway to 
activate factor X, leading to conversion of prothrombin (factor II) to thrombin 
(factor IIa) and culminating in the conversion of fibrinogen to fibrin, which 
becomes part of the clot. At each step, an enzyme converting an inactive precursor 
into an active enzyme often with the aid of Ca2+, membrane phospholipids or 
additional factors 9, 24.  
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Pathologic Hemostasis 
Bleeding disorders  
 Patients with blood coagulation disorders have more predispositions to 
excessive bleeding or thrombosis, and because of that, they become a serious 
challenge in the dental practice 25. 
Bleeding disorders can be classified as coagulation factor deficiencies, 
platelet disorders, vascular disorders or fibrinolytic defects (Table III). The most 
common are haemophilia A, haemophilia B and von Willebrand’s disease 26. 
 
 
 
 
Coagulation factor 
deficiencies 
Congenital 
Haemophilia A and B 
Von Willebrand’s disease 
Other factor deficiencies (rare) 
Acquired 
Liver disease 
Vitamin K deficiency, warfarin use 
Disseminated intravascular coagulation 
 
Platelet disorders 
Quantitative disorder (thrombocytopenia) 
Immune-mediated 
Idiopathic 
Drug-induced 
Collagen vascular disease 
Sarcoidosis 
Non-immune-mediated 
Disseminated intravascular coagulation 
Microangiopathic hemolytic anemia  
Leukemia 
Myelofibrosis 
 
Qualitative disorder 
Congenital 
Glanzmann thrombasthenia 
von Willebrand’s disease 
Acquired 
Drug-induced 
Liver disease 
Alcoholism 
 
Vascular disorders 
Scurvy 
Purpura 
Hereditary hemorrhagic telangiectasia 
Cushing syndrome 
Ehlers-Danlos syndrome 
Fibrinolytic defects Streptokinase therapy 
Disseminated intravascular coagulation 
 
 
Table III: Common bleeding disorder (Gupta A, et al. 2007) 26. 
 15 
 
Haemophilia A (factor VIII deficiency) is the most common hereditary 
coagulation disorder 25, associated with serious bleeding and accounts for about 
85% of haemophilia patients. It has an incidence of 1:5.000 in the male population. 
It is a sex-linked disorder. This X-linked recessive disorder is caused by a reduced 
amount of factor VIIl. Approximately 30% of cases are caused by new genetic 
mutations and therefore do not have a family history 27.   
Can be classified as severe (less than 1% of normal factor VIII activity), 
moderate (1-5% of normal activity), or mild (5-25% of normal activity) 25 and 
prolonged bleeding following a dental extraction can sometimes be the first sign of 
mild disease. Haemophilia is usually asymptomatic, although bleeding following 
minor trauma can be excessive 27.  
Factor VIII assay is required for diagnosis. These patients will have a normal 
bleeding time, normal platelet count and normal prothrombin time (PT), but a 
prolonged partial thromboplastin time (PTT) 27.  
Haemophilia B (factor IX deficiency) is much less common than haemophilia 
A; however, the clinical picture is very similar, with a prolongation of activated 
Partial Thromboplastin Time (aPTT). Some patients present an abnormal factor IX 
that slightly prolongs PT 25. Is inherited as X-linked recessive trait and results in 
reduced levels of factor IX. Account for approximately 15% of haemophilia 
patients. It has an incidence of 1:15.000 in the male population. This disorder is 
categorised as mild (factor IX levels >5%), moderate (1 -5%), or severe (<1 %) 27.  
There are 3types of haemophilia B 28: 
• Type 1 - Dominant Symptoms (tend to be mild) 
• Type 2 - Dominant Symptoms (tend to be mild) 
• Type 3 - Recessive Symptoms (tend to be severe) 
Von Willebrand's disease is a hereditary coagulation disorder characterized 
by a deficient or abnormal plasma protein known as the Von Willebrand Factor 
(vWF), whose physiological role is to stabilize Factor VIII and mediate platelet 
adherence. Thus, Factor VIII levels are low 17, 25. Increased easy bruising, epistaxis 
and significant oral surgical bleeding are the most common manifestations of the 
disease 17. The bleeding associated with the disease is of variable intensity.  
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The disorder is classified as follows: 
Type 1 Quantitative alterations of Von Willebrand factor: 
vWF concentration is below normal, the bleeding time 
and aPTT are prolonged, and F VIII concentrations are 
low 25. Partial deficiency (80% of those with vWD) 23. 
Type 2 Quanlitative alterations of Von Willebrand factor: 
vWF concentration is not below normal, but the factor is 
unable to stabilize F VIII and aggregate platelets, and thus 
bleeding time and aPTT are prolonged, and F VIII 
concentrations are low 23, 25. 
A Decreased function; absent medium and high-molecular-
weight multimers 23 
B Increased affinity for platelet GPIb; decreased high-
molecular-weight multimers 23 
M Decreased function; variable multimer pattern 23 
N Decreased affinity for FVIII 
Type 3 Severe deficiency of the total protein complex 17, 23; 
autosomal recessive  
Table IV: Classification of von Willebrand disease (Adapted from Israels S, et al. 2006) 23.  
 
Glanzmann thrombasthenia (GT) is a rare autosomal recessive bleeding 
disorder. Platelets from these patients fail to aggregate due to quantitative or 
qualitative defects of the integrin, αIIbβ3. In normal haemostasis, αIIbβ3 on 
activated platelets binds the adhesive proteins which form the protein bridges that 
link platelets during aggregation. Although GT platelets are able to adhere via 
other receptors, such as GPIb⁄IX⁄V complex, platelet spreading is defective in the 
absence of functional glycoprotein IIb/IIIa (αIIbβ3). As a consequence, the 
damaged vessel wall cannot be efficiently sealed, resulting in a bleeding 
phenotype. The platelet count and morphology are normal, the bleeding time is 
prolonged, and in vitro platelet aggregation is defective in response to various 
physiological platelet agonists 29. 
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Platelet-rich plasma in Oral Surgery 
Many studies have evaluated the use of PRP in the field of Dentistry, 
especially in small bone grafts in the alveolar region for future dental implants and 
in periodontal and maxillofacial surgery 13. 
Alissa et al. (2010) conducted a pilot study on the effect of PRP on the 
healing of the hard and soft tissues of extraction sockets and concluded that PRP 
may have additional benefits in reducing healing complications, because soft tissue 
healing was significantly improved in patients treated with PRP compared with 
patients that were not treated with PRP. Moreover, patients untreated with PRP 
experienced complications (dry sockets and alveolar osteitis), which were 
considered to be borderline statistically significant 30.  
Figure 7 – Periapical radiographs of PRP use (a) and control sockets, with no PRP use (b) at 12 weeks after tooth 
extraction. Adapted from: Alissa R, et al. (2010) (Without author permission) 30. 
 
The results of the combination of PRP with bone grafts have demonstrated 
more rapid consolidation and a mineralization of the graft in 50% of the time 
required, and an increase from 15 to 30% of the density of the trabecular bone and 
the efficiency of growth factors released by platelets occurs from the beginning of 
the surgery, contributing to bone formation from the first stage, determining the 
acceleration of tissue repair and bone producing a higher density 13. 
Dusse et al. (2008) and Sánchez et al. (2003) cited a clinical study from 
Anitua, where twenty patients undergoing dental extraction prior to implant 
placement were evaluated. Anitua found that the alveolar sockets treated with PRP 
showed greater buccal-lingual bone thickness and better epithelialization than the 
group that did not receive PRP (control group). This author reported the use of 
PRP in other 250 patients with evidence of clinical success 13, 19. 
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The same authors also mentioned Marx and Garg that suggested the use of 
PRP in cases with less chance of success in osseointegration and bone grafts, like in 
edentulism (severely resorbed jaw), in patients with osteoporosis, and in cases of 
dental disease with subsequent changes in nearby tissues 13, 19. 
Although there are still controversies about the benefits of PRP in bone 
regeneration, Daif (2012) reported that the direct application of PRP along the 
fracture lines can be regarded as a promising method for improving bone 
regeneration in mandibular fractures 31. 
 
Sánchez et al. (2003) also considered scientific evidence the use of PRP in 
combination with bone grafts in reconstructive surgery, noting the unanimous 
opinion of acceleration and improve of quality of the regenerated bone 19. 
A clinical study on immediate implant placement in severely resorbed 
maxillae using xenogenous and PRP products revealed an undoubted success 13. 
Dusse et al. (2008) mentioned Wojtowick et al., that observed the effects of 
the combination of PRP with xenogenous material, suggested that genetic 
mechanisms influence the organization of the trabecular pattern of the 
Figure 8 – Fracture line of the mandible treated with PRP. Adapted from: Daif et al. (2012) (Without author 
permission) 31. 
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regenerated bone tissue, probably under the influence of growth factors released 
by platelets 13. 
This author also avowed that a higher platelet count in PRP, after double 
centrifugation of the sample, reinforces the idea that different laboratory 
procedures for obtaining PRP may interfere decisively in the success of this 
preparation, minimizing the beneficial effect expected 13. 
Albanese et al. (2013) cited Gentile et al. study, where they emphasized the 
efficacy of the PRP treatment, post-operative patient’s satisfaction and advantages 
of faster healing on 15 cases, comprising reconstructive surgery of the jaw, oral 
implantology and post-extration alveolar bone regeneration 10.  
Por and co-workers (2009) showed in a meta-analysis about the use of 
tissue sealants in face-lifts that exists a strong trends towards the reduction of 
wound drainage and postoperative ecchymosis among patients who had used 
tissue sealants, such as PRP 32.   
Jadhav et al. (2013), presented 3 cases, where compare the clinical and 
radiographic treatment outcome of revascularization with and without PRP in 
immature, non-vital anterior teeth and found that PRP supplement improve the 
outcome of revascularization 33. 
Sammartino et al. (2005) showed that PRP is effective to induce bone 
regeneration and acceleration for the treatment of periodontal defects on the distal 
root of the second molar, after the surgical removal of an impacted mandibular 
third molar, with good results both clinically and histologically. Due to its content 
of fibrin, PRP allows stabilizing the blood coagulation, thereby promoting the 
regeneration of bone defects, particularly in the early stages 34. 
 
 
 
 
Figure 9 – Pre-operative X-ray showing the inferior third 
molar deeply impacted. Adapted from: Sammartino et al. 
(2005) (Without author permission) 45. 
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Figure 10 – (A) Preparation of the PRP gel. (B) The PRP gel is inserted into the post-extractive bone defect. (C) X-
ray showing bone regeneration at 12 weeks from the intervention. (D) X-ray showing the conserved osseous level 
18 weeks after the intervention. Adapted from: Sammartino et al. (2005) (Without author permission) 34. 
 
Sánchez et al (2011), showed significant benefits and a success in over 90% 
of patients in a study, where it was used PRP mixed with autologous bone graft for 
the closure of palatal fistulas by local mucoperiosteal flaps 35. 
 
 
 
 
 
 
 
 
Figure 11 – (A) Nasopalatine fistula (Pre-operative). (B) Post-operative after 4 months from the surgery. 
Adapted from: Sánchez et al. (2011) (Without author permission) 35. 
A B 
C D 
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Even though numerous studies confirm the PRP efficiency in the bone 
repair acceleration, Choi et al. (2004) in their research does not show any benefit 
in its use or even report the faster bone healing 36.  
 
 
 
 
 
Figure 12 – Frontal sections through the middle of defects. Large islands of connective tissue (arrowed) were 
seen throughout the defect in the PRP group (A), whereas the non-PRP group (B) showed extensive bone 
formation throughout the defect. Adapted from: Choi et al. (2004) (Without author permission) 36. 
 
 
 
 
 
Likewise, Albanese et al. (2013) mentioned Esposito, that said that 
treatments using PRP in sinus lift procedures did not seem to improve the clinical 
outcome and quoted a review of Khairy et al., that showed that enrichment with 
PRP did not significantly improve bone density in sinus which had been 
augmented with autogenous bone with PRP, compared to those without PRP 10. 
Arenaz-Bua et al. (2010), in a prospective study about the efficacy of PRP in 
promoting bone regeneration after third molar extraction, have not observed that 
PRP accelerates bone formation in post-extraction sockets, but established that 
PRP mixed with other biomaterials simplifies the manipulation of the graft and for 
that reason could be useful as a biological carrier in mandibular bone 
reconstruction 37. 
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Figure 13 – A mixture of autologous bone collected by filtration during the ostectomy and platelet-rich plasma is 
obtained (A) and applied in the postextraction socket (B). Note that PRP facilitates the manipulation of the 
particulate bone graft. The rest of the platelet-rich plasma obtained by the same method as above (C) is applied 
alone in the socket of the control side (D). Adapted from: Arenaz-Bua et al (2010) (Without author permission) 37. 
 
Anitua et al. (2008), in a study of BTI implants used in conjunction with 
PRP, with up to 5 years of follow-up, reported a 99.2% overall implant survival 
rates for 5.787 implants placed in 1.060 patients. The implants failures occurred in 
one half of the first year of loading, and in 70% of patients that had presented 
chronic or aggressive periodontitis 38. 
Posteriorly, Fabbro et al. (2009) studied the combination of PRP and 
immediate post-extraction implant placement and found excellent clinical results 
and high success rate in preservation of hard and soft tissues 39. 
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Figure 14 – (A) Periapical 
radiograph of second left 
maxillary premolar. (B) 
Extracted tooth, showing dentin 
caries in coronal portion and 
periapical lesion around apical 
third of root canal system. (C) 
Postextraction socket. (D) 
Activated PRP ready to be placed 
into alveolus. (E) Implant body 
embedded in PRP liquid to induce 
bioactivation of implant surface. 
(F) Titanium implant placement 
performed immediately after 
extraction. (G) Radiograph of 
implant soon after placement. 
(H) Radiograph obtained at 1 
year of follow-up.. Adapted from: 
Fabbro et al (2009) (Without 
author permission) 39. 
 
A B C 
D E 
F 
G H 
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Platelet-rich plasma in patients with bleeding disorders 
The incidence of postoperative bleeding after minor oral surgical 
procedures in patients with appropriate haemostasis is given with values between 
0.2% and 3.3%, while in chronically anticoagulated patients ranges between 8.6% 
and 32.1% 18. 
Use of autologous platelet-rich plasma has been reported in many situations 
in dentistry and oral surgery and implantology, for the stimulation and 
acceleration of tissue healing and bone regeneration 40.  
So what about using PRP in patients with bleeding disorders?  
There are a small number of studies and patients that can answer this 
question but Nurden et al (2011) published a clinical study where they use 
autologous platelet-rich clots for preventing local injury bleeding in patients with 
bleeding disorders 40. 
Four patients with a moderate-to-severe inherited bleeding syndrome were 
enrolled in the study (only three of them for doing oral surgeries) and all of them 
received 50mg/Kg of an antifibrinolytic agent, tranexamic acid (Exacyl, Sanofi-
Aventis, Paris,France), for four consecutive days starting the day before surgery. 
The clots were prepared from the patient’s own platelet-rich plasma after the 
addition of Ca2+ and placed on the injured site immediately after surgery 40.  
The first patient (a 60-year old woman), diagnosed with VWD type 2B at the 
time of study, had a platelet count of 47 000 platelets µL-1, with giant platelets and 
some small aggregates. It was performed a single extraction of the tooth 36 with 
alveolectomy under local anaesthesia (the cartridge also contained epinephrine) 40.  
The second patient (a 22- year old woman) also diagnosed with VWD, had a 
platelet count of 98 000 platelets µL-1, with giant platelets. She was submitted to 
extraction of three wisdom teeth (positions 18, 28 and 38) under general 
anaesthesia 40.  
The other patient is a 60-year old man, with type 1 GT, with no platelet 
aggregation, and less than 5% expression of the αIIbβ3 integrin on his platelets. 
His platelet count was normal, but platelet aggregation was absent. Extraction of 
two premolars and one molar was performed under local anaesthesia during his 
first visit and two molars were extracted during a second visit, two weeks later 40. 
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Paracetamol was given for pain management for all patients and non-
steroidal anti-inflammatory drugs were avoided 40. 
For all patients, the platelet-rich clot formed normally; the autologous clots 
formed after 20–30 minutes and were carefully placed into the cavity immediately 
after tooth extraction and held in place by closing and suturing the lesion 40. 
In the first patient no bleeding was observed at the site of her lesion 
following the application of her platelet-rich clot. Wound healing and bone 
formation occurred normally in the following weeks. For the second patient, the 
untoward bleeding was prevented and no vWF or platelet transfusion was 
required. In the last one, after tooth removal with local anaesthesia, some bleeding 
occurred at the points of needle puncture and during extraction, but as soon as the 
clots were placed in the dental cavity, bleeding stopped and did not restart during 
the following days 40. 
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Management of patients with bleeding disorders in dental procedures 
Hemorrhagic diseases have a major impact on the proper evaluation of 
medical and dental needs and individuality of each patient, so before any 
treatment, especially if it is a surgical procedure, the clinical history should be 
well-detailed and patients should be consulted about any spontaneous bleeding, 
episodes of previous unusual bleeding after injuries or surgeries, and easy or 
recurrent bruising 25, 26. 
The management and treatment of these patients depends on the severity of 
the bleeding disorder condition and the level of invasion of the planned dental 
procedure. The main objective is to decrease and minimize the patient’s risk by 
restoring the hemostatic system to acceptable levels and sustain hemostasis by 
local and adjunctive methods 26. 
So the dentist should take into consideration the following aspects 25: 
- The type of bleeding disorder involved; 
- The greatest dental treatment according to the disease; 
- Evaluate whether the standard treatment must be modified due to the 
requirements of dental treatment; 
- Evaluate which medication the patient is taking; 
- Evaluate the contraindicated medications; 
- Assess the half-life of the transfused factor and plan the procedure 
according to the values obtained;  
- Assess of whether conversion to heparin with INR control is required if the 
patient is receiving oral anticoagulation. 
To know which systemic therapy is the best suited for dental procedures, 
one should consult the patient's hematologist, because decisions about the type 
and the need for replacement of coagulation factor depend on the specific 
hemostatic diagnosis, the severity of bleeding and the type of  dental procedure 
which will be performed (more or less invasive). Table V shows the replace 
systemic therapy options for some patients. More severe disorders will require 
measures to temporarily increase the platelet count or improve its function 23. 
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Table V: Management of patients with coagulation factor deficiencies, who require dental extraction or complex 
procedures (Adapted from Israels S, et al. 2006) 24.  
 
The INR (International Normalized Ratio) is recommended to be monitored 
and measure of the extrinsic pathway of coagulation in the 24 hours before the 
dental procedure. It is calculated using the ratio of the prothrombin time (PT) of 
the patient and the mean PT of a plasma with normal reference values, corrected 
by the International Sensitivity Index (ISI) of the reagent used, which correlates 
the sensitivity of commercial thromboplastins with a reference one. It can be 
obtained by the formula INR = (PTR)ISI, where the PTR is the PT of the patient 
divided by the plasma with the reference value 41, 42. 
To Aframian D. et al (2007), patients who have an unstable INR or INR >3.5 
should be referred to their physician or hematologist for dose adjustment before 
invasive dental procedures 41 and Pototski M. et al (2007) consider that patients 
with INR above 4.0, shall not be subject to any surgical procedure without 
consulting the clinician responsible for the maintenance of their therapeutic 43. 
In a study, Bajkin B. et al (2009) demonstrated that minor surgical 
procedures such as tooth extractions, are safe to perform in hipocoagulated 
patients when the INR<4.0, using local hemostatic measures 44. Flap surgeries, 
implant placement and apicoectomies are not recommended in patients with an 
INR between 3.0-4.0 45.   
Bleeding 
disorder 
Pre-treatment for 
extraction or nerve block 
Post-extraction treatment 
for all bleeding disorders 
vWD, Type 1 Desmopressin, 0.3 μg/kg 
(maximum dose 20 μg) IV 
over 20–30 minutes or 
subcutaneously 
 
 
 
Antifibrinolytic agents (e.g., 
tranexamic acid, 25 mg/kg, 3 
times a day for 3–5 days 
 
Soft diet for 7 days 
 
Within 24 hours, assess need 
for repeat treatment 
vWD, Types 2A 
and 2M 
Desmopressin, as above, if 
tested response or Humate-
P, 50 IU of vWF:RCoF/kg 
vWD, Types 2B 
and 3 
Humate-P, 50 IU of 
vWF:RCoF/kg 
Haemophilia A 
(mild) 
Desmopressin, as above, if 
tested response is adequate 
Haemophilia A 
(moderate or 
severe) 
Recombinant Factor VIII 
concentrate, 20–25 IU/kg 
Re-evaluate post-procedure 
Haemophilia B 
(mild, moderate 
or severe) 
Recombinant Factor IX 
concentrate, 40–60 IU/kg 
Re-evaluate post-procedure 
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Dental management of patients with bleeding disorders using PRP 
For patients with bleeding disorders, the surgical procedures are always a 
source of difficulties, due to the risk of prolonged bleeding, such as dental 
extractions. Thus, the new technique based on the use of autologous platelet-rich 
clots (PRP), which act as both a physical barrier to blood loss as a source of growth 
factors promotes wound healing and reduces inflammation, because platelets 
activated, which contain large quantities of stored protein, stimulate cell 
proliferation and differentiation 40. 
If necessary, the patient's hematologist should be consulted before planning 
the surgery, and patients with severe disease should be treated in specialized 
centers. Local hemostatic agents and techniques, such as pressure and surgical 
sutures, can be used individually or in combination. It is necessary to be careful 
with the use of vasoconstrictors, because of the risk of rebound vasodilatation, 
which may increase late bleeding risk. The INR should be measured before some 
surgical procedures, and the normal range is between 2.0 and 3.0 26.  
PRP has the inconvenience that must be done freshly soon after blood 
extraction 46. Marx (2004) believed that true PRP is always autologous and is not 
homologous. The use of lyophilized donor platelets, homologous platelets, is not 
viable and does not secret bioactive growth factors. The platelets are also antigenic 
due to their abundance of cell membranes and, therefore, anti-platelet antibodies 
could develop from this reaction product and initiate second set reactions 47. 
However, a study performed by Vila V. et al (2013), about the influence of 
frozen plasma on the thrombin generation assay (TGA - the platelet absence causes 
a significant decrease in TGA), and using patients with severe haemophilia and 
with severe bleeding phenotype, showed that in PRP there were no differences in 
the results obtained from fresh or frozen samples. This result is in agreement with 
a previous report, which showed that freezing does not influence either the 
endogenous thrombin potential or the thrombin peak in PRP from healthy 
individuals. As PRP freezing did not affect the TGA, this fact opens the possibility of 
using frozen PRP to facilitate the clinical procedures in the workplace 46.  
With all the information, it may be speculated and set a protocol of care and 
management of patients with coagulation disorders, using PRP as an aid in 
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controlling bleeding after minimally invasive dental surgeries, like in dental 
extractions (Scheme 1). 
 
Experimental Protocol (Scheme 1) 
If necessary, and in agreement with the patient’s haematologist, it can be 
recommended the antifibrinolytic agent tranexamic acid 40, 48 (given orally 500mg, 
3 times a day for 7 days). Local anesthesia can be administered with 
vasoconstrictor (example: infiltration of 2% lidocaine with 1:80.000 epinephrine) 
48. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Local measures for haemorrhage, include minimally traumatic surgical 
technique; sectioning of difficult teeth, limiting the total number of dental 
extractions in one appointment; use of local haemostatic agents, use of sutures and 
use of local pressure with gauze packs can be performed 48.  
 
Blood extraction 
Centrifugation 
Fractionation 
PRP formulations can be used in oral surgery procedures 
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Conclusions 
Platelet-rich Plasma is a technique that has been proposed and used for 
several practises in dental and oral surgery. 
Many clinical cases have been reported in literature with high success rates, 
and with better results, when PRP is used to control postoperative bleeding and 
improve and accelerate the healing process and tissue repair.  
To establish the real benefit to the use of such preparations in dentistry and 
in other clinical areas, highly standardized and reliable methods for obtaining PRP 
should be used and developed by qualified professionals. Not only the number of 
platelet preparations should be observed, but also qualitative aspects, that is, the 
function of platelets. A considerable number of platelets, but with compromised 
viability, certainly will not provide the desired effect, because the growth factors 
are crucial to the success of preparation, and may have already been eliminated as 
a result of improper procedures. 
The prospects of using PRP, as well as the need for optimization of their 
preparation procedure, open new opportunities for professionals, especially in the 
field of hematology. In this work it was described a standardized and simple 
protocol that can be used for minor surgeries in Dentistry, for patients with 
bleeding disorders, using PRP to improve the quality and accomplishment of the 
treatments. The benefits include not only decreased bleeding, but also added 
security that will encourage patients to seek early help for painful local 
procedures. 
The PRP is defined as produced from autologous blood, however, in 
bleeding disorders, platelet function is modified (either by deficiencies in clotting 
factors or lack of adherence of platelets to subendothelium), so the question that 
arises is: PRP should be used from the patient own blood or from a donor with 
blood compatibility? In the only study ever conducted and published, referenced in 
this work, PRP was obtained from patient's own blood, nevertheless, studies on the 
properties and benefits of using PRP fresh/frozen (using a donor) showed no 
significant differences. Then, it can be concluded that both types of obtaining PRP 
(either autologous blood or compatible donor) can be used in such patients, not 
forgetting that own blood has its advantages, especially in immunological reactions 
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and communicable diseases. However, the small number of studies and patients 
contributed to a lack of more true and correct statistical evidences.  
A new generation of platelet concentrates with fibrin, PRF (Platelet-rich 
Fibrin), have been described in some studies to have higher success rate of healing 
compared to PRP results, because for their preparation, that requires neither 
anticoagulant nor bovine thrombin, or any other gelling agent. The absence of 
anticoagulant activates rapidly, most of the platelets from the blood sample in 
contact with the tube wall and starts the coagulation cascade. The fibrinogen is 
transformed into fibrin by circulating thrombin and a fibrin clot is formed, 
between acellular plasma and red blood cells in the tube 49.  
Notwithstanding, for patients with bleeding disorders, it is assumed that 
PRP is better, because due to coagulation and platelet adhesion disorders, the use 
of gelling agents, will promote more platelet counts in the end of the procedure of 
obtaining PRP. 
As a result it is required further studies, with larger sample sizes, to support 
the use of PRP in Dentistry current practice. 
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